Why the study?
Does adjunctive tirzepatide therapy improve weight loss and body composition in post-bariatric patients with insufficient weight loss or weight regain?
Population
21 post-bariatric patients without type 2 diabetes with insufficient weight loss or weight regain
Comparison
Adjunctive tirzepatide therapy over 6 months
Design
Retrospective study
Follow-up
6 months
Key result
Adjunctive tirzepatide therapy in post-bariatric patients with insufficient weight loss or weight regain resulted in a mean total weight loss of 12.0% at 6 months (p<0.001).
Authors
Loading...
Tirzepatide was associated with 12% weight loss in post-bariatric IWL/WR patients; leaves open whether adjunctive use should enter routine care pending RCTs.
Cohort (n=21)
Does adjunctive tirzepatide therapy improve weight loss and body composition in post-bariatric patients with insufficient weight loss or weight regain?
p-value: p=<0.001
Adjunctive tirzepatide therapy significantly enhances weight loss and improves metabolic health in post-bariatric surgery patients experiencing insufficient weight loss or weight regain.
Stoll et al. (2025) conducted a cohort in Insufficient weight loss or weight regain after metabolic bariatric surgery (n=21). Tirzepatide was evaluated on Mean total weight loss (p=<0.001). Adjunctive tirzepatide therapy in post-bariatric patients with insufficient weight loss or weight regain resulted in a mean total weight loss of 12.0% at 6 months (p<0.001).